Search Result

Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK
Targets Recommended:	CaMK CDK Raf Pim PI4K DNA-PK SRPK SGLT VDAC SNIPER PAK RIP kinase ERK PDK-1

Results for "

Calmodulin-dependent kinases

" in MCE Product Catalog:

By Targets:	CaMK (11) AMPK (2) Antibiotic (1) Apoptosis (1) Autophagy (9) Calcium Channel (1) EGFR (1) Myosin (1) P2X Receptor (1) Phosphodiesterase (PDE) (1) PKA (1) PKC (1) Src (1) Trk Receptor (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (1) Metabolic Disease (4) Neurological Disease (4)

12

Inhibitors & Agonists

4

Peptides

2

Natural
Products

Cat. No.	Product Name	Target	Research Areas

Lavendustin C	CaMK EGFR Src	Cancer
Lavendustin C is a potent *Ca²⁺ calmodulin-dependent* kinase II (CaMK II) inhibitor with an IC₅₀ of 0.2 µM. Lavendustin C inhibits EGFR*-associated tyrosine kinase* (IC₅₀=0.012 µM) and pp60^c-src(+) kinase (IC₅₀=0.5 µM) .

Calmodulin-Dependent Protein Kinase II (290-309)	CaMK Autophagy	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II.

Calmodulin-Dependent Protein Kinase II(290-309) acetate	CaMK Autophagy	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II.

HY-15465A

KN-93 hydrochloride
CaMK Autophagy Cancer

KN-93 hydrochloride is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a K_i of 370 nM.
HY-15465

KN-93
CaMK Autophagy Cancer

KN-93 is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a K_i of 370 nM.

Rimacalib SMP 114	CaMK Autophagy	Metabolic Disease
Rimacalib (SMP 114) is a *Ca²⁺/calmodulin-dependent* protein kinase II (CaMKII) inhibitor, with IC₅₀s of ~1 μM for CaMKIIα to ~30 μM for CaMKIIγ**.

STO-609	CaMK AMPK Autophagy	Metabolic Disease
STO-609 is a selective and cell-permeable inhibitor of the Ca²⁺/calmodulin-dependent protein kinase kinase (CaM-KK), with K_i values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC₅₀ ~0.02 g/ml.

KN-62	CaMK P2X Receptor Autophagy	Metabolic Disease Cancer
KN-62 is a selective and potent inhibitor of calmodulin-dependent protein kinase II (CaMK-II) with IC₅₀ of 0.9 μM, KN-62 also displays noncompetitive antagonism at P2X₇ receptors in HEK293 cells, with an IC₅₀ value of approximately 15 nM.

W-7 hydrochloride	CaMK Phosphodiesterase (PDE) Myosin Apoptosis	Cancer
W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca²⁺-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC₅₀ values of 28 μM and 51 µM, respectively. W-7 hydrochloride induces apoptosis and has antitumor activity.

K-252a SF2370; Antibiotic K 252a; Antibiotic SF 2370	PKC PKA CaMK Trk Receptor Autophagy Antibiotic	Infection Inflammation/Immunology
K-252a, a staurosporine analog, inhibits protein kinase, with IC₅₀ values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively. K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene.

Autocamtide 2 Autocamtide II	CaMK Autophagy	Neurological Disease
Autocamtide 2 is a highly selective peptide substrate of calcium/calmodulin-dependent protein kinase II (CaMKII). It can be used in the CaMKII activity assay.

Gomisin J	AMPK Calcium Channel	Metabolic Disease Cardiovascular Disease
Gomisin J is a small molecular weight lignan found in Schisandra chinensis and has been demonstrated to have vasodilatory activity. Gomisin J suppresses lipid accumulation by regulating the expression of lipogenic and lipolytic enzymes and inflammatory molecules through activation of AMPK, LKB1 and *Ca²⁺/calmodulin-dependent* protein kinase II and inhibition of fetuin-A** in HepG2 cells. gomisin J has potential benefits in treating nonalcoholic fatty liver disease.

Cat. No.	Product Name	Target	Research Area

Calmodulin-Dependent Protein Kinase II (290-309)	CaMK Autophagy	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II.

Calmodulin-Dependent Protein Kinase II(290-309) acetate	CaMK Autophagy	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II.

Calmodulin-Dependent Protein Kinase II (281-309)	Peptides	Neurological Disease
Calmodulin-Dependent Protein Kinase II (281-309) is a peptide of calcium/calmodulin-dependent protein kinase II (CaM-kinase II).

Autocamtide 2 Autocamtide II	CaMK Autophagy	Neurological Disease
Autocamtide 2 is a highly selective peptide substrate of calcium/calmodulin-dependent protein kinase II (CaMKII). It can be used in the CaMKII activity assay.

Cat. No.	Product Name	Target	Category

K-252a SF2370; Antibiotic K 252a; Antibiotic SF 2370	PKC PKA CaMK Trk Receptor Autophagy Antibiotic	Natural Products
K-252a, a staurosporine analog, inhibits protein kinase, with IC₅₀ values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively. K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene.

Gomisin J	AMPK Calcium Channel	Phenylpropanoids
Gomisin J is a small molecular weight lignan found in Schisandra chinensis and has been demonstrated to have vasodilatory activity. Gomisin J suppresses lipid accumulation by regulating the expression of lipogenic and lipolytic enzymes and inflammatory molecules through activation of AMPK, LKB1 and *Ca²⁺/calmodulin-dependent* protein kinase II and inhibition of fetuin-A** in HepG2 cells. gomisin J has potential benefits in treating nonalcoholic fatty liver disease.

MCE Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Intellectual Property Promise; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Terms & Conditions

Resources: Free Sample; Literature; Molarity Calculator; Dilution Calculator

Subscribe to our E-newsletter

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2021 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us